Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims

Core Viewpoint - Julie & Holleman LLP is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp, raising concerns about the fairness of the $105 per share deal price, which may be undervalued compared to potential estimates of $136.25 per share [1][2][3] Group 1: Acquisition Details - The acquisition deal was announced in November 2025 and is expected to close in the second quarter of 2026 [2] - Exact Sciences filed a preliminary proxy statement with the SEC on December 29, 2025, indicating that no other bidders were considered during the acquisition process [2] Group 2: Legal Investigation - Julie & Holleman LLP is investigating potential claims regarding the apparent unfairness of the deal and possible conflicts of interest [3] - The firm has a history of securing hundreds of millions of dollars for clients in similar cases, indicating their experience in shareholder litigation [3][4]